Patient Safety inNon-Surgical Facial Aesthetics

Non-surgical facial aesthetics sits in a regulatory twilight: botulinum toxin is generally regulated as a prescription medicine, while facial fillers are commonly regulated as medical devices — even though both are injected into one of the most anatomically unforgiving parts of the body. Across the systems reviewed, most injectable complications are minor and self-limiting, but the serious ones are time-critical, anatomy-dependent and often underreported.

A 2024 meta-analysis of 20 RCTs found botulinum toxin A had a low overall adverse-event burden. For fillers, the most feared events — vascular occlusion, skin necrosis, blindness — are documented predominantly through retrospective cohorts, case series and surveillance datasets, sharply lowering certainty for incidence estimates.

The strongest policy conclusion is simple: the field should be specialty-open but competency-locked. Facial aesthetics should not be the exclusive preserve of dermatology or plastic surgery, but neither should it remain a market where short courses and weak reporting substitute for anatomy, supervision and accountability.

The MAUDE post-market dataset is the largest openly analysed record of dermal-filler complications in the US. The top-reported events are inflammatory and infectious, not catastrophic — but note that MAUDE reports are proportions of reported events, not incidence per treatment.

In a US retrospective cohort of 370 dermatologists spanning over 1.6 million syringes, microcannulas were associated with a 77.1% lower odds of occlusion than needles. Instrument choice matters — but so does injector experience, plane and anatomical region.

Certainty (GRADE-style): moderate for BoNT short-term safety; low for comparative filler AEs; very low for population incidence of blindness and occlusion.

Progression is not calendar-based. It is based on what a practitioner can safely be trusted to do, in which region, under which conditions, with what rescue capability.

Real safety in aesthetics is layered. Product assurance without injector assurance is weak. Injector assurance without premises assurance is weak. All of it without feedback loops is theatre.

1. 1

   Regulate aesthetic medicine as an independent competency domain — not a casual add-on and not a specialty monopoly.

2. 2

   Credential by anatomy, not by procedure. Lips, nose, tear trough, forehead/glabella, temple, and lower-face volumisation are separate privileges.

3. 3

   Do not legislate a universal case-number threshold as if it were evidence. Use hybrid entrustment criteria: supervised exposure, structured assessment, complication drills, outcome audit.

4. 4

   Every filler injector must have immediate access to a vascular-occlusion protocol, hyaluronidase, emergency kit, photographic documentation, and a documented pathway for visual symptoms.

5. 5

   Mandatory reporting of serious AEs and a national registry — capturing product, batch, injector background, site, plane, instrument, complication, treatment and outcome.

6. 6

   Recognise ultrasound as a meaningful adjunct for high-risk practice, complication diagnosis and anatomy teaching — not a magic wand, but not optional at the top of the pyramid.

The sector’s long-running mistake has been to confuse popularity with maturity. In the literature reviewed, the safer environments are not those with the loudest branding or the oldest specialty title; they are the ones with clearer competence boundaries, better product controls, more realistic consent, faster recognition of complications, and stronger routes for escalation and learning.

A country that takes non-surgical aesthetics seriously should be able to answer three questions without blinking: who is allowed to inject, where are they allowed to inject, and what happens when it goes wrong. At present, too many systems can answer only the first half of the first question.

Competing interests. The authors report no manufacturer funding. They are affiliated with the Harley Street Institute, an independent privately-run educational academy. The Harley Street Framework is presented as a transparent policy proposal informed by the evidence reviewed, not as a regulator-issued standard.

• Alam M, et al. Rates of vascular occlusion associated with using needles vs cannulas for filler injection. JAMA Dermatology. 2021.
• Xiong M, et al. Retrospective analysis of the MAUDE database on dermal filler complications 2014–2020. JAAD. 2022.
• Beleznay K, Carruthers JDA, Humphrey S, Jones D. Update on Avoiding and Treating Blindness From Fillers. Aesthetic Surgery Journal. 2019.
• Vasconcelos Berg R, et al. Best practices for high-frequency ultrasound to guide aesthetic filler injections. Diagnostics. 2024.
• MHRA / UKHSA. Iatrogenic botulism cluster, England. Public warnings, 2025.
• AHPRA & National Boards. Cosmetic procedures guidelines. 2025.
• Singapore Medical Council. Guidelines on Aesthetic Practices for Doctors. 2016.
• European Commission. MDR Annex XVI — products without an intended medical purpose.
• FDA. Dermal Fillers Approved by the Center for Devices and Radiological Health.
• JCCP / CPSA. Competency Framework for the Cosmetic Sector.